Featured Research

from universities, journals, and other organizations

Targeted treatment plus chemotherapy could benefit women with ovarian cancer

Date:
October 11, 2013
Source:
Institute of Cancer Research
Summary:
Conventional chemotherapy could further extend life in some women with ovarian cancer when used in tandem with a new type of targeted treatment, a new international study shows. The research provides important evidence that PARP inhibitor drugs and chemotherapy can both be effective in the same patients, helping women live longer than they would if treated with chemotherapy alone.

Conventional chemotherapy could further extend life in some women with ovarian cancer when used in tandem with a new type of targeted treatment, a new international study shows.

Related Articles


The research, published in the October issue of the journal Clinical Cancer Research, provides important evidence that PARP inhibitor drugs and chemotherapy can both be effective in the same patients, helping women live longer than they would if treated with chemotherapy alone.

The study, in women with mutations to BRCA genes -- which increase the risk that ovarian cancer will relapse after treatment, as well as being linked to breast and other cancers -- showed that ovarian cancers that have become resistant to PARP inhibitors often remain sensitive to conventional chemotherapy.

The study was led by researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, and looked at follow-up data from patients who had previously taken part in clinical trials sponsored by pharmaceutical company AstraZeneca. The research was supported by grants from the Experimental Cancer Medicine Centre and a range of institutions including Cancer Research UK, the National Institute for Health Research and the Wellcome Trust.

The researchers monitored 89 patients with BRCA-mutated ovarian cancer at The Royal Marsden and other hospitals in the UK, Australia, Belgium, Israel and North America, all of whom received chemotherapy following the development of resistance to a PARP inhibitor called olaparib.

Almost half (49 per cent) of olaparib-resistant patients showed a significant decrease in the size of their tumours when subsequently treated with platinum-based chemotherapy, a frequently-used treatment in ovarian cancer. The results show that a significant proportion of women with ovarian cancer could live longer if they received both treatments.

PARP inhibitors have the advantage of causing fewer and less toxic side-effects than traditional chemotherapy. They are being developed in clinical trials worldwide as a potential 'personalised' treatment for women with BRCA gene mutations, although some have also shown some benefit in patients with non-BRCA tumours.

The researchers also used high-tech new sequencing techniques to probe the precise genetic mechanisms responsible for drug resistance in ovarian tumours. Previously, tumours were thought to evolve resistance to both PARP inhibitors and platinum chemotherapy by acquiring new, secondary mutations to BRCA genes -- transforming BRCA proteins from mutated, non-functioning forms back into working proteins.

However, in a small subset of six cases, the study found no sign of secondary BRCA mutations, suggesting that at least in these cases, cancer was developing resistance to PARP inhibitors and platinum-based chemotherapy in different ways.

Study leader Professor Stan Kaye, Cancer Research UK Professor of Medical Oncology at The Institute of Cancer Research, and Consultant at the Royal Marsden, said:

"Our study finds that for many women with ovarian cancer, it is not a case of either/or chemotherapy or PARP inhibitors -- there is a good chance that they may respond to both. Although some scientists were concerned that using PARP inhibitors would prevent chemotherapy from being effective, we've resolved that concern by showing that both drug types can work in the same patients.

"Ovarian cancer is a difficult disease to treat and our research does underline the complexity of cancer, and the many different routes it can use to become resistant to treatment. But it also presents us with an opportunity, by showing us that two different types of drug treatment given in sequence could potentially extend lives."


Story Source:

The above story is based on materials provided by Institute of Cancer Research. Note: Materials may be edited for content and length.


Journal Reference:

  1. J. E. Ang, C. Gourley, C. B. Powell, H. High, R. Shapira-Frommer, V. Castonguay, J. De Greve, T. Atkinson, T. A. Yap, S. Sandhu, S. Banerjee, L.-M. Chen, M. L. Friedlander, B. Kaufman, A. M. Oza, U. Matulonis, L. J. Barber, I. Kozarewa, K. Fenwick, I. Assiotis, J. Campbell, L. Chen, J. S. de Bono, M. E. Gore, C. J. Lord, A. Ashworth, S. B. Kaye. Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study. Clinical Cancer Research, 2013; 19 (19): 5485 DOI: 10.1158/1078-0432.CCR-13-1262

Cite This Page:

Institute of Cancer Research. "Targeted treatment plus chemotherapy could benefit women with ovarian cancer." ScienceDaily. ScienceDaily, 11 October 2013. <www.sciencedaily.com/releases/2013/10/131011101225.htm>.
Institute of Cancer Research. (2013, October 11). Targeted treatment plus chemotherapy could benefit women with ovarian cancer. ScienceDaily. Retrieved April 1, 2015 from www.sciencedaily.com/releases/2013/10/131011101225.htm
Institute of Cancer Research. "Targeted treatment plus chemotherapy could benefit women with ovarian cancer." ScienceDaily. www.sciencedaily.com/releases/2013/10/131011101225.htm (accessed April 1, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Wednesday, April 1, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

7-Year-Old Girl Gets 3-D Printed 'robohand'

7-Year-Old Girl Gets 3-D Printed 'robohand'

AP (Mar. 31, 2015) — Although she never had much interest in prosthetic limbs before, Faith Lennox couldn&apos;t wait to slip on her new robohand. The 7-year-old, who lost part of her left arm when she was a baby, grabbed it as soon as it came off a 3-D printer. (March 31) Video provided by AP
Powered by NewsLook.com
Solitair Device Aims to Takes Guesswork out of Sun Safety

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015) — The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins